Tildacerfont for Congenital Adrenal Hyperplasia

"Forty-two clinical sites across the United States are actively recruiting patients for this trial. These locations span from Boston and Baltimore to Orange, as well as numerous other areas in between - you should select a site closer to your residence so that travel demands remain low if accepted into the study."

"According to clinicaltrials.gov, this trial is currently enrolling patients. This study was initially published on August 26th 2020 and has been recently revised November 4th 2022."

"The primary efficacy outcome of this 12-week trial is the alteration in androstenedione. Secondary objectives include a safety analysis, measurement of A4 levels below the upper limit of normal values, as well as assessment of any changes to TART(s) lesion volume for male CAH subjects over up to 12 months."

"This clinical trial is searching for 72 individuals, aged 18 to 55, diagnosed with congenital adrenal hyperplasia. In addition to this criteria, the participants must be of any gender over 18 years old and have a genetic mutation in CYP21A2 or elevated 17-OHP levels which are treated with hormonal corticosteroids at doses between 15 - 60 milligrams per day. Furthermore, those with salt wasting forms require stable mineralocorticoid replacement treatment periods that exceed 1 month before screening begins."

"The requisite criteria for enrolment in this trial necessitate that participants are aged 18 to 55. Meanwhile, 28 and 105 trials respectively cater to those below 18 or above 65 years of age."

"Affirmative. According to clinicaltrials.gov, this research is actively seeking participants; the trial was first published on August 26th 2020 and has been recently updated on November 4th 2022. The study seeks a total of 72 individuals from 42 distinct sites."

"Our team at Power has assigned the safety of Tildacerfont Group 3 a rating of 2, as there is existing evidence that it is harmless yet no data to affirm its efficacy."